Analysts Bullish + Strong Clinical Data Send Relay Therapeutics Shares Up Nearly 15% for the Week

The stock price of Relay Therapeutics (RLAY) surged nearly 15% this week, primarily driven by a bullish analyst report, positive clinical data for its core drug RLY-2608, and improved financial performance.

Bullish Analyst Report Boosts Confidence 

Brad Canino, an analyst at Guggenheim Securities, issued a report after market close on Wednesday, initiating coverage of Relay Therapeutics with a “Buy” rating. He set a $15 price target, representing significant upside compared to the stock’s closing price before the report. Canino named Relay Therapeutics a “top pick,” particularly highlighting the potential of its oral drug RLY-2608 in late-stage breast cancer trials and its favorable safety profile. He also mentioned RLY-2608’s potential application in treating vascular malformations, a rare disease most commonly found in children. Additionally, Canino noted that the company’s current stock price is below its cash value, which may attract investors seeking undervalued opportunities.

Core Drug RLY-2608 Shows Positive Clinical Data 

RLY-2608 is an investigational therapy targeting breast cancer patients with PI3Kα mutations. Interim data from its ReDiscover study are encouraging: 

• The median progression-free survival (PFS) was 9.2 months across all mutation types, and PFS extended to 10.3 months in patients with kinase domain mutations. For context, Barclays analysts noted that the current standard second-line treatment for HR+/HER2- breast cancer achieves a PFS of approximately 5.5 to 6 months. 
• Among 30 patients with measurable disease, the objective response rate (ORR) reached 33% (meaning one-third of patients achieved partial response), and nearly three-quarters of patients experienced tumor shrinkage. 
• The combination therapy was well-tolerated, with only a small number of patients discontinuing treatment due to treatment-related adverse events, and a low incidence of Grade 3 hyperglycemia.

These positive data support RLY-2608’s potential to become a new treatment option that competes with existing drugs, such as AstraZeneca’s Truqap. The company expects to engage with regulatory authorities and initiate pivotal studies in 2025.

Improved Financial Performance Provides Support 

In addition to positive R&D progress, Relay Therapeutics has recently shown improved financial conditions: 

• The company reported a profit of $677,000 in the second quarter, compared to zero earnings in the same period last year. 
• Its net loss per share narrowed by 41% to $0.41. 
• Although there are some financial warning signs (such as an Altman Z-Score of 2.8 and a Piotroski F-Score of 3), the company maintains a relatively solid cash position, a healthy interest coverage ratio, and a Beneish M-Score of -4.12, indicating a low likelihood of financial manipulation.

The recent rise in Relay Therapeutics’ stock price reflects market optimism toward the clinical prospects of its core drug RLY-2608, strong analyst endorsement, and recognition of its improved financial performance. However, investing in biotechnology stocks typically involves high risks, and long-term performance will depend on the success of subsequent clinical trials and eventual regulatory approval. Continuous monitoring of the company’s R&D progress and financial condition remains essential.

Healthcare Services Life Science Nutraceutical Pharmaceutical